Literature DB >> 3965439

Elimination half-life and bioavailability of haloperidol in schizophrenic patients.

J R Magliozzi, L E Hollister.   

Abstract

Haloperidol was administered orally to 6 male schizophrenic patients and intravenously to 3. Elimination half-life (t1/2 beta) and bioavailability (F) were calculated for both groups from haloperidol serum concentrations determined by gas-liquid chromatography. Mean (+/- SD) half-lives were 17.5 +/- 8.7 hours for oral administration and 15.1 +/- 2.5 hours for intravenous; bioavailability was 0.64 +/- 0.23. These values were comparable to those found in normal volunteers.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3965439

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN： 0160-6689            Impact factor:   4.384


  10 in total

1.  Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol.

Authors:  W H Chang; Y W Lam; M W Jann; H Chen
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Pharmacokinetics of haloperidol in psychotic patients.

Authors:  Y F Cheng; L K Paalzow; U Bondesson; B Ekblom; K Eriksson; S O Eriksson; A Lindberg; L Lindström
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 3.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 4.  Haloperidol dosing strategies in the treatment of delirium in the critically ill.

Authors:  Erica H Z Wang; Vincent H Mabasa; Gabriel W Loh; Mary H H Ensom
Journal:  Neurocrit Care       Date:  2012-02       Impact factor: 3.210

5.  Pharmacokinetics and bioavailability of benperidol in schizophrenic patients after intravenous and two different kinds of oral application.

Authors:  W Seiler; H Wetzel; A Hillert; G Schöllnhammer; M Langer; U Barlage; C Hiemke
Journal:  Psychopharmacology (Berl)       Date:  1994-12       Impact factor: 4.530

Review 6.  Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients.

Authors:  B K Wagner; D A O'Hara
Journal:  Clin Pharmacokinet       Date:  1997-12       Impact factor: 6.447

Review 7.  Pharmacokinetics of haloperidol.

Authors:  J S Froemming; Y W Lam; M W Jann; C M Davis
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

8.  Gender-Specific Differences in Low-Dose Haloperidol Response for Prevention of Postoperative Nausea and Vomiting: A Register-Based Cohort Study.

Authors:  Florian Brettner; Silke Janitza; Kathrin Prüll; Ernst Weninger; Ulrich Mansmann; Helmut Küchenhoff; Alexander Jovanovic; Bernhard Pollwein; Daniel Chappell; Bernhard Zwissler; Vera von Dossow
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

9.  Population pharmacokinetics of haloperidol in terminally ill adult patients.

Authors:  L G Franken; R A A Mathot; A D Masman; F P M Baar; D Tibboel; T van Gelder; B C P Koch; B C M de Winter
Journal:  Eur J Clin Pharmacol       Date:  2017-07-05       Impact factor: 2.953

10.  Pharmacokinetics of Haloperidol in Critically Ill Patients: Is There an Association with Inflammation?

Authors:  Letao Li; Sebastiaan D T Sassen; Mathieu van der Jagt; Henrik Endeman; Birgit C P Koch; Nicole G M Hunfeld
Journal:  Pharmaceutics       Date:  2022-02-28       Impact factor: 6.321
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.